@article {Jat:September 2006:1081-1206:397,
author = "Jat, Gokul C.",
author = "Mathew, Joseph L.",
author = "Singh, Meenu",
title = "Treatment with 400 g of inhaled budesonide vs 200 g of inhaled budesonide and oral montelukast in children with moderate persistent asthma: randomized controlled trial",
journal = "Annals of Allergy, Asthma and Immunology",
volume = "97",
year = "September 2006",
abstract = "Background: Montelukast is reported to be beneficial in asthma as add-on therapy to inhaled corticosteroids and may reduce the need for the latter. Objective: To evaluate whether a combination of oral montelukast and 200 μg of inhaled budesonide has comparable efficacy to 400 μg of inhaled budesonide alone in children with moderate persistent asthma. Methods: In this prospective, blinded, hospital-based randomized controlled trial, 71 children with moderate persistent asthma were randomized to receive either montelukast, 5-mg chewable tablet, with 200 μg of inhaled budesonide or only 400 μg of inhaled budesonide daily for 12 weeks. Baseline and serial measurements of forced expiratory volume in 1 second, peak expiratory flow rate, and Asthma Symptom Score were performed; the frequency and severity of exacerbations were also recorded. Results: Measurements of forced expiratory volume in 1 second, peak expiratory flow rate, and Asthma Symptom Score showed no significant differences between the 2 groups at baseline, during the serial follow-up visits, and at the end of the study. However, children who received montelukast had a greater frequency of exacerbations vs those who did not (33.3% vs 9.1%; P < .01). Conclusion: The overall control of asthma with 5 mg of oral montelukast and 200 μg of inhaled budesonide is inferior to that with 400 μg of inhaled budesonide in children with moderate persistent asthma.",
pages = "397-401(5)",
url = "http://www.ingentaconnect.com/content/acaai/aaai/2006/00000097/00000003/art00022"
}